FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316077755> ?p ?o ?g. }

• W4316077755 endingPage "e548" @default.
• W4316077755 startingPage "e548" @default.
• W4316077755 abstract "Introduction: Crohn’s disease (CD) is characterized by transmural inflammation and ongoing inflammatory activity, which over time results in the accumulation of bowel damage, which may lead to complications such as strictures, fistulas/fissures, and abscesses, as well as disability. Optimally controlling inflammation early in the disease course of CD, during the ‘window of opportunity,’ may be the best way to change disease course. Recent evidence and clinical practice guidelines suggest that early biologic therapy is preferred in treating moderate to severe CD. Early use of biologic therapy and achievement of mucosal healing can contribute to disease course modification. We hypothesize that significantly more CD patients treated within 2 years of diagnosis will achieve clinical remission and have less CD-related complications than those treated 2 or more years after diagnosis. Methods: We conducted a retrospective cohort study of CD patients treated within the Military Health System to assess the relationship of timing of initiation of biologic therapy with the control of CD. Data was collected from January 1, 2013 to December 30, 2020 to measure the course of patients’ disease as determined by clinical, biochemical, radiologic, and endoscopic/histologic findings, with an assessment of clinical outcomes and complications to include CD-related emergency room visits, steroid use, hospitalizations, and surgeries. Results: 343 patients with CD were identified, of which 184 were started on biologic therapy within 2 years of diagnosis, while 159 were started on biologic therapy 2 or more years after diagnosis. Patients who initiated biologic therapy within 2 years of diagnosis had significantly fewer CD-related complications (p< 0.0001) (Figure 1a). Evidence of perianal disease at diagnosis was predictive of an increased likelihood of CD-related complications (Figure 1b). Patients on monotherapy with thiopurines prior to biologic therapy were also more likely to experience CD-related complications (Figure 1c). Conclusion: These findings demonstrate that earlier initiation of biologics (within 2 years of diagnosis) results in a lower probability of CD-related complications, including emergency room visits, steroid use, hospitalizations, and surgeries. This real-world study is one of the first to confirm prior clinical trial data on decreased complications in early initiation of biologic therapy in CD patients.Figure 1.: Survival curves for complications with respect to timing of biologic start (1a), presence of perianal disease (1b) and thiopurine therapy prior to biologic stat (1c)." @default.
• W4316077755 created "2023-01-14" @default.
• W4316077755 creator A5002938685 @default.
• W4316077755 creator A5020193167 @default.
• W4316077755 creator A5021378665 @default.
• W4316077755 creator A5027382814 @default.
• W4316077755 creator A5050174560 @default.
• W4316077755 creator A5063806091 @default.
• W4316077755 creator A5080691892 @default.
• W4316077755 creator A5083609138 @default.
• W4316077755 date "2022-10-01" @default.
• W4316077755 modified "2023-09-26" @default.
• W4316077755 title "S771 Impact of Early Biologic Therapy in Real-World Cohort of Crohn’s Disease Patients" @default.
• W4316077755 doi "https://doi.org/10.14309/01.ajg.0000859724.83110.90" @default.
• W4316077755 hasPublicationYear "2022" @default.
• W4316077755 type Work @default.
• W4316077755 citedByCount "0" @default.
• W4316077755 crossrefType "journal-article" @default.
• W4316077755 hasAuthorship W4316077755A5002938685 @default.
• W4316077755 hasAuthorship W4316077755A5020193167 @default.
• W4316077755 hasAuthorship W4316077755A5021378665 @default.
• W4316077755 hasAuthorship W4316077755A5027382814 @default.
• W4316077755 hasAuthorship W4316077755A5050174560 @default.
• W4316077755 hasAuthorship W4316077755A5063806091 @default.
• W4316077755 hasAuthorship W4316077755A5080691892 @default.
• W4316077755 hasAuthorship W4316077755A5083609138 @default.
• W4316077755 hasBestOaLocation W43160777551 @default.
• W4316077755 hasConcept C126322002 @default.
• W4316077755 hasConcept C167135981 @default.
• W4316077755 hasConcept C201903717 @default.
• W4316077755 hasConcept C2778260677 @default.
• W4316077755 hasConcept C2779134260 @default.
• W4316077755 hasConcept C2779280984 @default.
• W4316077755 hasConcept C71924100 @default.
• W4316077755 hasConcept C72563966 @default.
• W4316077755 hasConceptScore W4316077755C126322002 @default.
• W4316077755 hasConceptScore W4316077755C167135981 @default.
• W4316077755 hasConceptScore W4316077755C201903717 @default.
• W4316077755 hasConceptScore W4316077755C2778260677 @default.
• W4316077755 hasConceptScore W4316077755C2779134260 @default.
• W4316077755 hasConceptScore W4316077755C2779280984 @default.
• W4316077755 hasConceptScore W4316077755C71924100 @default.
• W4316077755 hasConceptScore W4316077755C72563966 @default.
• W4316077755 hasIssue "10S" @default.
• W4316077755 hasLocation W43160777551 @default.
• W4316077755 hasLocation W43160777552 @default.
• W4316077755 hasOpenAccess W4316077755 @default.
• W4316077755 hasPrimaryLocation W43160777551 @default.
• W4316077755 hasRelatedWork W149565788 @default.
• W4316077755 hasRelatedWork W2013349448 @default.
• W4316077755 hasRelatedWork W2069635508 @default.
• W4316077755 hasRelatedWork W2106015740 @default.
• W4316077755 hasRelatedWork W2605850428 @default.
• W4316077755 hasRelatedWork W3022661331 @default.
• W4316077755 hasRelatedWork W3043725575 @default.
• W4316077755 hasRelatedWork W3093766579 @default.
• W4316077755 hasRelatedWork W4224289230 @default.
• W4316077755 hasRelatedWork W4254700653 @default.
• W4316077755 hasVolume "117" @default.
• W4316077755 isParatext "false" @default.
• W4316077755 isRetracted "false" @default.
• W4316077755 workType "article" @default.